Literature DB >> 18395253

Circumvention of glucocorticoid resistance in childhood leukemia.

E G Haarman1, G J L Kaspers, R Pieters, M M A Rottier, A J P Veerman.   

Abstract

In this study, we determined if in vitro resistance to prednisolone and dexamethasone could be circumvented by cortivazol or methylprednisolone, or reversed by meta-iodobenzylguanidine in pediatric lymphoblastic and myeloid leukemia. As there were strong correlations between the LC50 values (drug concentration inducing 50% leukemic cell kill, LCK) of the different glucocorticoids and median prednisolone/methylprednisolone, prednisolone/dexamethasone and prednisolone/cortivazol LC50 ratios did not differ between the leukemia subtypes, we conclude that none of the glucocorticoids had preferential anti-leukemic activity. Meta-iodobenzylguanidine however, partially reversed glucocorticoid resistance in 19% of the lymphoblastic leukemia samples.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18395253     DOI: 10.1016/j.leukres.2008.02.009

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

Review 1.  Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.

Authors:  David T Teachey; Stephan A Grupp; Valerie I Brown
Journal:  Br J Haematol       Date:  2009-03-16       Impact factor: 6.998

2.  Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response.

Authors:  Sebastiaan D T Sassen; Ron A A Mathôt; Rob Pieters; Valérie de Haas; Gertjan J L Kaspers; Cor van den Bos; Wim J E Tissing; D Maroeska W W Te Loo; Marc B Bierings; Inge M van der Sluis; C Michel Zwaan
Journal:  Br J Haematol       Date:  2021-06-01       Impact factor: 6.998

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.